Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q3 EPS of $0.34 beat the $0.21 estimate, and the company raised its 2026 outlook for the third time. Shares gained about 19% through November 4, while quarterly free cash flow was positive and leverage declined.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠EBITDA Improvement ⢠Debt Burden ⢠Weak Coverage BLCO shows improving profitability and cash flow at a low valuation, but high debt, weak interest coverage, and intangible-heavy assets warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Neutral momentum Support Level: $17.13â$17.20 Resistance Level: $17.55â$17.80 BLCO's last-month downtrend and lower highs favor caution unless it reclaims $17.55â$17.80, while a break below $17.13â$17.20 could extend losses.
Sentiment & News
Key News Insights: ⢠Phase III Progress ⢠SeeLyra Approval ⢠Lens Performance Bausch + Lomb advanced its pipeline and surgical portfolio with Phase III progress, CE Mark approval for SeeLyra, and supportive lens data, strengthening its eye-care growth outlook.
AI Summary
BLCO's improving growth, 13% EBITDA margin, and positive free cash flow suggest a credible operating turnaround, but the equity remains constrained until these gains consistently lift interest coverage above 1x against its $5.1B debt load; investors should wait for durable cash conversion and deleveraging before assigning a full rerating.
Description
Bausch + Lomb is a global eye health company organized into three operating segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. Its Vision Care unit supplies contact lenses, lens care solutions and overâtheâcounter eye care products, the Pharmaceuticals unit develops proprietary and generic medicines and therapeutic lenses for postâoperative care and conditions such as glaucoma and retinal disease, and the Surgical unit produces intraocular lenses, delivery systems and equipment for cataract and vitreoretinal procedures. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 5 | Nov 12 | BLCO | Bausch + Lomb Corporation | Q3 EPS of $0.34 beat the $0.21 estimate, and the company raised its 2026 outlook for the third time. Shares gained about 19% through November 4, while quarterly free cash flow was positive and leverage declined. | Active | +0.0% |